Medical news and careers, clearly connected
CareZelo
English
Menu

Updates zur öffentlichen Gesundheit

Öffentliche GesundheitKanada

Baxter to discontinue 200 mg cyclophosphamide intravenous solution by year end 2026

Baxter Corporation reports its Procytox (cyclophosphamide) 200 mg powder for intravenous solution (DIN 02241797) will be discontinued on Dec 31, 2026, for business reasons. The discontinuation decision will not be reversed.

Cyclophosphamide is a standard chemotherapy drug — cancer care teams should plan the switch to another strength or product before Dec 31.

Discontinuation date: 31. Dez. 2026 Alle Fristen

Frage zu diesem Bericht stellen

Die Antworten werden von einer KI auf Basis dieses Berichts erstellt und können fehlerhaft sein. Überprüfen Sie die Originalquelle, bevor Sie handeln.

2 kostenlose Fragen pro Tag ohne Konto. Mitglieder können unbegrenzt und kostenlos Fragen stellen.

Keine medizinische, rechtliche oder einwanderungsbezogene Beratung. Fragen werden anonym gespeichert, um unsere Berichte zu verbessern.

Original lesen

Offizielle Quelle: Baxter to discontinue 200 mg cyclophosphamide intravenous solution by year end 2026 (öffnet in neuem Tab) — Health Product Shortages Canada

Problem melden

Fällig in 20 TagenÖffentliche GesundheitKanada

Accel Pharma reports upcoming two-week shortage of ondansetron 8 mg tablets

Accel Pharma reports its ondansetron orally-disintegrating tablet 8 mg (ACCEL-ONDANSETRON ODT, DIN 02535327) faces an anticipated shortage from Nov 1 to Nov 15, 2026, caused by a shortage of an active ingredient.

Ondansetron is a widely used anti-nausea drug — pharmacies should check stock and alternatives before the anticipated shortage starts Nov 1.

Offizielle Quelle: Health Product Shortages Canada (öffnet in neuem Tab)

Fällig in 20 TagenÖffentliche GesundheitKanada

Accel Pharma reports upcoming two-week shortage of ondansetron 4 mg tablets

Accel Pharma reports its ondansetron orally-disintegrating tablet 4 mg (ACCEL-ONDANSETRON ODT, DIN 02535319) faces an anticipated shortage from Nov 1 to Nov 15, 2026, caused by a shortage of an active ingredient.

Ondansetron is a widely used anti-nausea drug — pharmacies should check stock and alternatives before the anticipated shortage starts Nov 1.

Offizielle Quelle: Health Product Shortages Canada (öffnet in neuem Tab)

Fällig in 39 TagenÖffentliche GesundheitKanada

Sandoz rabeprazole 20 mg supply disruption expected until early December

Sandoz Canada reports its rabeprazole sodium 20 mg enteric-coated tablet (DIN 02314185) faces an anticipated shortage from Oct 26 to Dec 4, 2026, after a disruption in the manufacture of the drug.

Rabeprazole is a commonly prescribed stomach-acid drug — prescribers and pharmacies should plan alternatives while the shortage is expected.

Offizielle Quelle: Health Product Shortages Canada (öffnet in neuem Tab)

Fällig in 18 TagenÖffentliche GesundheitKanada

Sandoz dexamethasone injection supply faces temporary shortage through mid-November

Sandoz Canada reports its dexamethasone sodium phosphate injection 10 mg/mL (DIN 00874582), for intravenous, intramuscular or intrasynovial use, faces an anticipated shortage from Oct 26 to Nov 13, 2026, driven by increased demand.

Dexamethasone injection is a staple steroid in hospitals and clinics — care teams should check stock before the anticipated shortage bites.

Offizielle Quelle: Health Product Shortages Canada (öffnet in neuem Tab)